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Interleukin-2 (IL-2) is a critical cytokine for the homeostasis
and function of forkhead box p3–expressing regulatory T cells
(Foxp3+Tregs). Dysregulation of the IL-2–IL-2 receptor axis is
associated with aberrant Foxp3+Tregs and T cell–mediated au-
toimmune diseases such as type 1 diabetes. Treatment with
recombinant IL-2 has been reported to enhance Foxp3+Tregs
and suppress different models of autoimmunity. However, effi-
cacy of IL-2 therapy is dependent on achieving sufficient levels
of IL-2 to boost tissue-resident Foxp3+Tregs while avoiding the
potential toxic effects of systemic IL-2. With this in mind, adeno-
associated virus (AAV) vector gene delivery was used to localize
IL-2 expression to the islets of NOD mice. Injection of a double-
stranded AAV vector encoding IL-2 driven by a mouse insulin
promoter (dsAAVmIP-IL2) increased Foxp3+Tregs in the islets
but not the draining pancreatic lymph nodes. Islet Foxp3+Tregs
in dsAAVmIP-IL2–treated NOD mice exhibited enhanced fitness
marked by increased expression of Bcl-2, proliferation, and sup-
pressor function. In contrast, ectopic IL-2 had no significant ef-
fect on conventional islet-infiltrating effector T cells. Notably,
b-cell–specific IL-2 expression suppressed late preclinical type 1
diabetes in NOD mice. Collectively, these findings demonstrate
that b-cell–specific IL-2 expands an islet-resident Foxp3+Tregs
pool that effectively suppresses ongoing type 1 diabetes long term.
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T
ype 1 diabetes is a T-cell–mediated autoimmune
disease in which the insulin-producing b-cells in
the pancreatic islets of Langerhans are destroyed
(1–3). Studies in at-risk individuals, type 1 diabetic
patients, and NOD mice have shown that the breakdown
in b-cell–specific T-cell tolerance is multifactorial, leading
to impaired peripheral immunoregulation (1–3). The di-
abetogenic response is characterized by a progressive but
nondestructive infiltration of the islets by CD4+ and CD8+
effector T cells (Teffs), forkhead box p3–expressing Tregs
(Foxp3+Tregs), and other immune effectors in NOD mice
(4). This innocuous insulitis then progresses to a de-
structive stage, leading to b-cell depletion and clinical
type 1 diabetes. Recently, it has become evident that the
transition to destructive insulitis is in part due to impaired
islet-resident Foxp3+Tregs in NOD mice (5–8).
Foxp3+Tregs are dependent on interleukin-2 (IL-2) for
maintenance of Foxp3 gene expression, survival, pro-
liferation, and suppressor function (9–12). However, un-
like conventional T cells, Foxp3+Tregs do not express IL-2
and consequently are dependent on Teffs and dendritic
cells as IL-2 sources (12–14). Dysregulation of the IL-2–IL-2
receptor (IL-2R) pathway contributes to the impaired
Foxp3+Treg pool in NOD mice and type 1 diabetic patients
(15–17). In NOD mice, decreased IL-2 production by Teffs
and dendritic cells, a defect mapping to the insulin-
dependent diabetes (Idd3) locus containing the Il2 gene,
correlates with reduced Foxp3+Treg survival (15–20).
Aberrant Foxp3+Treg survival in NOD mice is detected
only in the islets and not in the draining pancreatic
lymph nodes (PLNs), a site for differentiation of path-
ogenic Teffs and various Treg subsets (15–17). In con-
trast, FOXP3+Tregs obtained from peripheral blood of
type 1 diabetic patients exhibit deficient IL-2R signaling
in vitro, evident by reduced phosphorylation of signal
tranducer and activator of transcription 5 (pSTAT5), a tran-
scription factor that regulates Foxp3+Treg-dependent
genes (21).
In view of the potent effects of IL-2 on Foxp3+Tregs,
recombinant (r)IL-2 therapy has garnered significant in-
terest for the treatment of chronic inflammation, trans-
plantation, and autoimmunity. The pleiotropic and potentially
toxic effects resulting from IL-2 stimulation of conven-
tional T cells and other immune effectors has led to sys-
temic administration of low doses of rIL-2. Low-dose rIL-2
therapy exploits the ability of Foxp3+Tregs, which consti-
tutively express CD25 and the corresponding high-affinity
IL-2R, to outcompete other immune effectors when IL-2 is
limiting (22). Clinical studies have shown that low-dose
rIL-2 therapy is protective in graft-versus-host disease and
hepatitis C virus–induced vasculitis (23,24). In addition,
b-cell autoimmunity is prevented and/or suppressed in NOD
mice following treatment with low-dose rIL-2, rIL-2–anti–
IL-2 antibody complexes, or a tetracycline-inducible adeno-
associated virus (AAV) vector expressing IL-2 systemically
by enhancing the Foxp3+Treg pool (16,25–29). A recent
phase I/II trial testing rIL-2 and rapamycin in type 1 di-
abetic patients, however, reported only a transient in-
crease in FOXP3+Tregs (30), possibly reflecting the need
for elevated and persistent levels of IL-2. Furthermore,
treatment resulted in an increase in activated natural killer
(NK) cells and eosinophils and an accelerated loss of in-
sulin C-peptide levels, suggesting exacerbated b-cell au-
toimmunity. These clinical findings highlight the potential
therapeutic benefit as well as the difficulty in achieving
a balance between efficacy and the unwanted pleiotropic
and systemic activity of IL-2.
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Accordingly, we have assessed the use of AAV vectors to
increase local IL-2 levels in the islets and enhance the
resident Foxp3+Treg pool in vivo. AAV vectors are non-
replicating, noncytopathic, nonintegrating, and arguably
the most effective and safe strategy to deliver genes in vivo
(31). Indeed, AAV vectors have been successfully applied
in the clinic to complement various genetic disorders (32–
34). AAV vectors transduce both dividing and nondividing
cells, and the availability of several serotypes and newly
engineered vectors permit targeting of a broad range of
cell types and tissues in vivo. Furthermore, selective trans-
gene expression can be achieved with cell-specific promoters
(35,36). Coupled with the development of self-complementary
or double stranded (ds)AAV vectors (37,38), as well as the
recent advances in manufacturing and purification, AAV
vectors provide an approach to sustain long-term trans-
gene expression in vivo. In the current study, we demon-
strate that dsAAV vector–mediated IL-2 expression by
b-cells selectively increases the frequency and function of
islet Foxp3+Tregs to effectively suppress type 1 diabetes
long-term.
RESEARCH DESIGN AND METHODS
Mice. NOD/LtJ, NOD.CB17-Prkdcscid/J (NOD.scid), NOD.Ca2/2, NOD.BDC
(39), NOD.BDC.Foxp3GFP (40), and NOD.8.3 (41) mice were bred and main-
tained under specific pathogen-free conditions in an American Association
for Laboratory Accreditation–accredited animal facility. NOD mice were di-
agnosed as diabetic after three consecutive blood glucose readings .250 mg/
dL. All procedures were approved by the University of North Carolina Animal
Use and Care Committee.
dsAAV vector engineering, packaging, and vaccination. Full-length cDNA
encoding murine Il2 (of the NOD genotype) and EGFP were subcloned into
a dsAAV plasmid (37) containing the murine preproinsulin II promoter (mIP).
dsAAV vector packaging was carried out as previously described (42). Briefly,
HEK 293T cells were cotransfected via polyethyleneimine with adeno
helper plasmid (pXX6–80), AAV8 capsid plasmid, and dsAAVmIP-IL2/enhanced
green fluorescent protein (EGFP) plasmid. Nuclear fractions were harvested
72 h posttransfection and packaged vector purified with a Cesium Chloride
(RPI Corp.) gradient. Vector containing fractions and titers were determined
by Southern dot blot. NOD mice were vaccinated intraperitoneally with
dsAAV8mIP-IL2 or dsAAV8mIP-EGFP.
ELISA. The anti–IL-2 antibody set (JES6-1 and JES6-5; eBioscience) was used
at a concentration of 2 mg/mL on a high binding ELISA plate (Costar) to
measure IL-2 levels in serum and islet cultures. Interferon-g (IFN-g) was
measured with the mouse IFN-g ELISA set (BD optEIA; BD Biosciences) as
per the manufacturer’s recommendations.
Islet isolation and streptozotocin treatment. Pancreases were perfused
with 2 mg/mL collagenase P (Roche) and digested for 30 min at 37°C. Islets
were purified via Ficoll gradient, handpicked, and counted. For flow cytom-
etry analysis, lymphocytes were collected from freshly isolated islets after
culturing in RMPI complete medium for a minimum of 4 h at 37°C and filtered
through a 70-micron nylon mesh.
NOD mice were treated intraperitoneally with 200 mg/kg of streptozotocin
(STZ; Sigma-Aldrich), resuspended in fresh sodium citrate buffer (pH 4.0), and
72 h later vaccinated intraperitoneally with AAV8mIP-IL2 or left untreated.
Blood glucose levels and serum IL-2 were assessed over 10 days post–rAAV
vector vaccination.
Flow cytometry. Cells from various tissues were stained with previously ti-
trated fluorochrome-conjugated monoclonal antibodies specific for: CD3 (145-
2C11), CD4 (GK1.5), CD8 (Ly-2), CD25 (PC61.5), CD62L (MEL-14), glucocorticoid-
induced tumor necrosis factor receptor–related protein (GITR, DTA-1), inducible
costimulator (ICOS, 7E.17G9), cytotoxic T lymphocyte–associated antigen-4
(CTLA-4, UC10-4F10-11), and Foxp3 (FJK-16s). Fc receptors were blocked
with rat anti-mouse CD16/32 (2.4G2; BD Biosciences) prior to staining. Intra-
cellular KI67 (B56; BD Biosciences) and Bcl-2 (3F11; BD Biosciences) staining
was done using the Fix/Perm and Perm/Wash reagents (eBioscience) according
to the manufacturer’s recommendations.
Intracellular cytokine staining was performed on single-cell suspen-
sions as previously described (43). Briefly, lymphocytes were stimulated with
500 ng/mL phorbol myristic acid (Sigma-Aldrich) and 1,000 ng/mL ionomycin
(Sigma-Aldrich) in complete RPMI medium for 5 h at 37°C and then treated
with 10 mg/mL brefeldin A (Sigma-Aldrich) for 4 h. Cells were stained for
surface molecules, fixed, and permeabilized with Cytofix/Cytoperm (BD
Biosciences) and stained for intracellular IFN-g (XMG1.2) or IL-10 (JES5-
16E3). For pSTAT5 staining, tissues were immediately processed in PBS
containing 2% paraformaldehyde. Single-cell suspensions were incubated on
ice for 20 min, centrifuged, and resuspended in ice-cold methanol for 30 min.
Cells were then counted, washed twice in 1% BSA in PBS, and stained with
anti-pSTAT5 antibody (47/Stat5 [pY694]; BD Biosciences) for 1 h on ice. Data
were acquired on a Cyan flow cytometer (DakoCytomation) and analyzed
using Summit software (DakoCytomation).
In vitro suppressor assay. Islets were pooled from NOD.BDC.Foxp3GFP mice
vaccinated with 2.5 3 1010 vector particles (VPs) of AAV8mIP-IL2 or AAV8-
mIP-EGFP, and single-cell suspensions stained with CD4- and CD3-specific
antibodies in PBS supplemented with 2.5% BSA and 2 mmol/L EDTA.
CD4+CD3+GFP+ Tregs were sorted on a MoFlo sorter (DakoCytomation).
For T cell responders, naive CD4+CD62L+ splenocytes were isolated from
NOD.BDC mice using the CD4+CD62L+ T cell isolation kit II (Miltenyi
Biotec) and labeled with Cell Trace Violet (Invitrogen) as per the manu-
facturer’s recommendations. Cell purity in naive populations was .95% by
flow cytometry. Splenocytes from NOD.Ca2/2 mice pulsed with 1 mg/mL
sBDC mimetic peptide were used as antigen-presenting cells (APCs). Na-
ive BDC CD4+ T cells (2.5 3 104), APCs (2.5 3 104), and varying ratios of
Foxp3+Tregs were cocultured in complete RPMI medium for 72 h and pro-
liferation of BDC CD4+ T cells assessed by dilution of Cell Trace Violet via flow
cytometry.
RESULTS
b-Cell–expressed IL-2 increases islet Foxp3+Tregs.
To target transgene expression to b-cells, dsAAV8mIP-IL2
encoding IL-2 driven by mIP was engineered. The serotype
capsid 8 protein used to package the AAV vector has
b-cell–specific tropism (35,36). IL-2 was detected in cul-
tures of islets prepared from NOD.scid mice injected in-
traperitoneally with dsAAV8mIP-IL2, confirming ectopic
IL-2 expression by b-cells in vivo (Fig. 1A). No IL-2 was
observed in supernatants from single-cell suspensions of
liver or heart (data not shown), which are major tissues
transduced in vivo by AAV8 vectors (44). Persistent low
levels of IL-2 were detected in the serum of 10–12-week-old
NOD female mice treated with dsAAV8mIP-IL2 (Fig. 1B).
Reduction of b-cell mass by STZ injection prior to dsAAV8-
mIP-IL2 vaccination significantly decreased serum IL-2 levels
(Fig. 1C), further indicating ectopic IL-2 expression by b-cells
in vivo. No difference in the frequency of conventional
CD4+ and CD8+ T cells, B cells (CD19+B220+), and NK
cells (DX5+) was detected in the blood of dsAAV8mIP-
IL2–vaccinated animals compared with control groups
(Fig. 1D).
The effect of increased local IL-2 on islet and PLN
Foxp3+Tregs was examined in 12-week-old NOD female
mice 4 weeks after dsAAV8mIP-IL2 treatment. The fre-
quency and number of islet Foxp3+Tregs were increased
up to two-fold in NOD mice treated with dsAAV8mIP-IL2
compared with animals injected with dsAAV8mIP-EGFP or
left untreated (Fig. 2A and B). Notably, no significant ef-
fect on PLN Foxp3+Tregs was detected after treatment
(Fig. 2A and B), suggesting that dsAAV8mIP-IL2 adminis-
tration preferentially affected islet Foxp3+Tregs.
Phenotypic analyses demonstrated that the frequency
of islet CD62LHIFoxp3+Tregs was significantly increased
in dsAAV8mIP-IL2–treated versus control animals (Fig.
2C). In addition, the level of CD25 expression by islet
Foxp3+Tregs, based on mean fluorescence intensity,
was elevated in a dsAAV8mIP-IL2 dose-dependent man-
ner (Fig. 2A and D). In contrast, the frequency of islet
Foxp3+Treg-expressing CTLA-4, GITR, and ICOS and
the levels of expression of the respective molecules were
similar between the dsAAV8mIP-IL2 and control groups
(Supplementary Fig. 1). Unlike the islets, the phenotype
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FIG. 1. In vivo b-cell expression of IL-2 after dsAAV8mIP-IL2 injection. A: IL-2 levels in supernatants from islets isolated from NOD.scid mice
treated with dsAAV8mIP-IL2 or left untreated. **P < 0.01, ***P < 0.001, one-way ANOVA 6 SEM. B: Temporal measurement of serum IL-2 from
10–12-week-old NOD female mice (n = 5) treated with dsAAV8mIP-IL2, dsAAV8mIP-EGFP, or left untreated. ***P < 0.001, two-way ANOVA 6
SEM. C: Serum IL-2 levels in NOD mice (n = 5) treated with STZ alone, STZ plus AAV8mIP-IL2 (2.5 3 1010 VPs) 72 h later, or AAV8mIP-IL2 (2.5 3
10
10
VPs) alone at day 10 post–STZ injection. ***P < 0.001, two-way ANOVA 6 SEM. D: Frequency of immune effector cells in peripheral blood of
NOD mice left untreated or treated with dsAAV8mIP-IL2 7, 14, and 21 days later. STZ, streptozotocin.
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of PLN Foxp3+Tregs was unaffected by dsAAV8mIP-IL2
vaccination (Fig. 2).
In contrast to islet Foxp3+Tregs, no change in the number
of conventional IFN-g+CD4+ and CD8+ Teffs was detected
in the islets of dsAAV8mIP-IL2–treated NOD mice (Fig. 2E ).
However, the ratio between the pool of IFN-g+ Teffs and
Foxp3+Tregs in the islets but not PLNs was decreased in
dsAAV8mIP-IL2 versus untreated and dsAAV8mIP-EGFP
cohorts (Fig. 2F).
To determine if the increased islet Foxp3+Treg pool
correlated with elevated IL-2R signaling, levels of pSTAT5
were measured. Up to 50% of islet Foxp3+Tregs were
pSTAT5+, reflecting an ;10-fold increase in dsAAV8mIP-
IL2 versus control groups (Fig. 3A). Only a modest two-fold
FIG. 2. The frequency and number of islet Foxp3
+
Tregs are increased after short-term dsAAV8mIP-IL2 treatment. A: CD3+CD4+ T cells were gated






T cells in the PLNs and islets of groups of 6–10 NOD female mice 4 weeks posttreatment with







T cells recovered from 70–100 islets/mouse. *P < 0.05, two-way ANOVA 6 SEM. Frequency of CD62LHI (C) and CD25 mean







T cells (E) and the ratio of IFN-g+ Teffs to Foxp3+Tregs in the PLN and islets (F) of the respective treatment groups. **P< 1022,
***P < 1023, two-way ANOVA 6 SEM.
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increase in the frequency of pSTAT5+ cells was detected in
conventional Foxp32CD4+ T cells in the islets of NOD
mice vaccinated with 2.5 3 1010 VPs dsAAV8mIP-IL2
(6.46 1.1%) relative to control animals (3.66 0.6%) (Fig. 3B).
In contrast, levels of pSTAT5 detected in Foxp3+Tregs or
Foxp32CD4+ T cells in the PLNs were unaffected by b-cell–
specific IL-2 (Fig. 3). Together, these findings demon-
strate that b-cell–specific IL-2 expression results in an
increased pool of phenotypically distinct islet but not
PLN Foxp3+Tregs marked by elevated IL-2R signaling.
b-Cell–expressed IL-2 enhances the fitness of islet
Foxp3
+
Tregs. Enhanced survival and/or expansion of
Foxp3+Tregs may explain the increased islet Foxp3+Treg
pool in dsAAV8mIP-IL2–treated animals. To determine if
AAV8mIP-IL2 vaccination increased islet Foxp3+Treg sur-
vival, expression of the antiapoptotic protein Bcl-2 was mea-
sured. The level of Bcl-2-expression following dsAAV8mIP-IL2
treatment was increased in islet Foxp3+Tregs (Fig. 4A) and
a trend toward an elevated frequency of Bcl-2+ Foxp3+Tregs
observed (Fig. 4B). In contrast, Bcl-2 expression was
unaffected in PLN Foxp3+Tregs (Fig. 4A and B) or in islet
IFN-g+CD4+ and CD8+ Teffs (Fig. 4C ).
Proliferation of islet and PLN Foxp3+Tregs after
dsAAV8mIP-IL2 administration was analyzed by KI67 staining.
The frequency of KI67+Foxp3+CD25+ T cells was signifi-
cantly increased in the islets by 8 days post–dsAAV8mIP-
IL2 treatment (Fig. 4D). In contrast, the frequency of
KI67+Foxp3+CD25+ T cells in the PLNs remained unchanged
over time (Fig. 4D), as was the frequency of KI67-staining
islet IFN-g+CD4+ and CD8+ Teffs (Fig. 4E ).
Next, the influence of b-cell–specific IL-2 on islet
Foxp3+Treg suppressor activity was assessed. NOD.BDC
mice transgenic for a Foxp3–internal ribosome entry site–
GFP reporter cassette (NOD.BDC.Foxp3GFP) were vacci-
nated with dsAAV8mIP-IL2 or dsAAV8mIP-EGFP and
GFP+Foxp3+Tregs sorted from the islets 4 weeks later. The
capacity of the respective Foxp3+Tregs to suppress Cell Trace
Violet–labeled naive BDC CD4+ T cells following stimulation
by peptide-pulsed APC was then measured. Islet Foxp3+Tregs
from dsAAV8mIP-IL2–treated NOD.BDC.Foxp3GFP mice
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(A) and Foxp32CD4+ (B) T cells in 10–12-week-old NOD female mice (n = 5) 4 weeks posttreatment with
AAV8mIP-IL2 or left untreated determined. ***P < 1023, two-way ANOVA 6 SEM.
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T cells in the PLNs and islets of NOD female
mice (n = 5) treated with AAV8mIP-IL2 (2.5 3 1010 VPs) or left untreated were assessed for the level (A) and frequency (B) of Bcl-2 expression.
*P < 0.05, two-way ANOVA 6 SEM. C: Bcl-2 expression for IFN-g+CD3+CD4+ and IFN-g+CD3+CD8+ Teffs in the PLNs and islets at days 5 and
8 posttreatment with AAV8mIP-IL2 or in untreated NOD mice (n = 5). The frequency of KI67+Foxp3+CD25+CD4+ T cells (D) and KI67+ IFN-g+Teffs
in the PLN and islets (E). *P < 0.05, ***P< 1023, two-way ANOVA 6 SEM. F: In vitro proliferation of Cell Trace–labeled BDC CD62L+CD4+ T cells






T cells isolated from pooled islets of AAV8mIP-IL2 (2.5 3 1010 VPs) or
AAV8mIP-EGFP–treated (2.5 3 1010 VPs) NOD.BDC.Foxp3GFP mice. **P < 1022, ***P < 1023, two-way ANOVA 6 SEM. MFI, mean fluorescence
intensity.
AAV VECTOR–MEDIATED MODIFICATION OF b-CELLS
3780 DIABETES, VOL. 62, NOVEMBER 2013 diabetes.diabetesjournals.org
exhibited significantly increased suppressor activity com-
pared with islet Foxp3+Tregs isolated from dsAAV8mIP-
EGFP donors at all ratios tested (Fig. 4F). Together, these
results demonstrate that b-cell–specific IL-2 enhances the
fitness of islet Foxp3+Tregs characterized by increased
Bcl-2 expression, proliferation, and suppressor function.
Type 1 diabetes is prevented at a late preclinical stage
in NOD mice by b-cell–expressed IL-2. Since b-cell–
specific IL-2 expression increased islet Foxp3+Tregs, the
efficacy of AAV8mIP-IL2 to suppress ongoing b-cell au-
toimmunity and prevent overt diabetes was examined. NOD
female mice 12 or 16 weeks of age, representing late
preclinical stages of type 1 diabetes, received a single
intraperitoneal injection of dsAAV8mIP-IL2, dsAAV8mIP-
EGFP, or were left untreated, and diabetes was moni-
tored. All NOD female mice treated with 2.5 3 1010 VPs of
dsAAV8mIP-IL2 at either 12 or 16 weeks of age remained
diabetes-free (Fig. 5A and B). Similarly, the frequency of
diabetes was significantly reduced in NOD female mice
treated at 12 weeks of age with 13 1010 VPs of dsAAV8mIP-
IL2 (2 of 8) relative to animals left untreated (18 of 22) or
receiving 2.5 3 1010 VPs dsAAV8mIP-EGFP (10 of 10)
(Fig. 5A). The latter indicated that diabetes protection was
not attributed to a nonspecific effect of dsAAV vector trans-
duction of b-cells.
Diabetes-free NOD mice at 35 weeks of age exhibited
a higher frequency of islet Foxp3+Tregs in dsAAV8mIP-
IL2 versus control groups, while no marked difference
in the PLNs was observed (Fig. 5C). Furthermore, islet
Foxp3+Tregs of dsAAV8mIP-IL2–treated NOD mice were
characterized by an increased frequency of CD62LHI
Foxp3+Tregs (Fig. 5D). Additionally, the ratio of IFN-g+
Teffs to Foxp3+Tregs was decreased in the islets of
dsAAV8mIP-IL2–treated NOD mice compared with normo-
glycemic untreated controls (Fig. 5E). No difference, how-
ever, was detected in the IFN-g+ Teffs to Foxp3+Tregs ratio
for PLN of dsAAV8mIP-IL2–vaccinated animals (Fig. 5E).
These results demonstrate that b-cell–specific IL-2 expres-
sion effectively suppresses ongoing autoimmunity long-term
by enhancing the islet Foxp3+Treg pool.
DISCUSSION
IL-2 is essential for the homeostasis of Foxp3+Tregs, and
dysregulation of the IL-2–IL-2R axis has been linked to
aberrant Foxp3+Treg survival and/or function in NOD mice
and type 1 diabetic patients (9–12). Systemic administra-
tion of low-dose rIL-2 or IL-2–antibody complexes is ef-
fective in preventing ongoing b-cell autoimmunity in NOD
mice (16,25–29). Nevertheless, achieving a protective ver-
sus proinflammatory response via systemic rIL-2 delivery
can be problematic. For instance, systemic low-dose rIL-2
plus rapamycin resulted only in a transient increase in
FOXP3+Tregs in type 1 diabetic subjects, and b-cell func-
tion declined, suggesting exacerbated autoimmunity (30).
Our results demonstrate that dsAAV vector–mediated tar-
geting of IL-2 expression to b-cells is an effective strategy
to manipulate the islet Foxp3+Treg pool and diabetogenic
response, while avoiding complications associated with
systemic delivery of rIL-2.
A key finding made in this study was the differential ef-
fect of b-cell–specific IL-2 on islet-infiltrating Foxp3+Tregs
and Teffs (Fig. 2). Elevated local levels of IL-2 resulted in
marked expansion of islet Foxp3+Tregs but not Teffs. This
observation is consistent with studies demonstrating that
Foxp3+Tregs are more sensitive to IL-2 compared with
naive T cells and Teffs, partly due to constitutive expression
of CD25 by Foxp3+Tregs (45). Indeed, the level and fre-
quency of IL-2R signaling as measured by pSTAT5 was
significantly increased in islet Foxp3+Tregs versus Teffs in
dsAAV8mIP-IL2–treated NOD mice (Fig. 3). No effect of
b-cell–specific IL-2 expression on PLN-resident Foxp3+-
Tregs was detected (Figs. 2 and 3), presumably due to b-cell
secretion of low levels of IL-2 into the bloodstream and not
the lymphatics. The increased number of islet Foxp3+-
Tregs correlated with enhanced proliferation early after
dsAAV8mIP-IL2 treatment (Fig. 4D). Interestingly, islet
Foxp3+Tregs division was reduced compared with un-
treated animals 4 weeks post–dsAAV8mIP-IL2 vaccina-
tion (Fig. 4D). This result suggests that homeostasis is
achieved overtime within the Foxp3+Treg pool despite
increased local levels of IL-2 and elevated IL-2R signaling
(Fig. 3). Accordingly, long-term maintenance of islet
Foxp3+Tregs in dsAAV8mIP-IL2–treated animals (Fig. 5C
and D) is likely due to enhanced survival, reflected by
increased expression of anti-apoptotic Bcl-2 (Fig. 4A)
and Bcl-xL (Supplementary Fig. 2) as opposed to per-
sistent levels of elevated Foxp3+Treg proliferation in the
islets.
In addition to increasing the size of the pool, b-cell–
specific IL-2 also induced qualitative changes in islet
Foxp3+Tregs. For instance, up to a four-fold increase in
suppressor activity was detected in vitro by BDC peptide–
specific islet Foxp3+Tregs from dsAAV8mIP-IL2–treated
NOD.BDC.Foxp3GFP mice (Fig. 4F). The latter may be
explained by the approximate two-fold increase in the
frequency of CD62LHI Foxp3+Tregs in the islets of
dsAAV8mIP-IL2–treated NOD mice (Fig. 2C). We and others
(6,19,46,47) have reported that CD62LHI versus CD62LLO
Foxp3+Tregs exhibit increased suppressor activity and that
elevated systemic levels of IL-2 promote expansion of
CD62LHI Foxp3+Tregs in vivo. An increase in the general
fitness of islet Foxp3+Tregs, marked by elevated levels of
CD25 and anti-apoptotic molecules for instance, may also
contribute to more robust suppressor function. Enhanced
islet Foxp3+Treg suppression, however, did not correlate
with elevated levels of IL-10 or transforming growth factor-
b1 expression (data not shown).
Importantly, increases in islet Foxp3+Tregs by b-cell–
expressed IL-2 were sufficient to suppress ongoing b-cell
autoimmunity at late preclinical stages and prevent the
onset of diabetes long-term (Fig. 5A and B). Initial efforts
to induce remission in recent-onset diabetic NOD mice by
dsAAV8mIP-IL2 vaccination have proven to be unsuccessful
(Supplementary Fig. 3). The latter may be due to an in-
sufficient b-cell pool that can be transduced, thereby lim-
iting local levels of IL-2 (Supplementary Fig. 3). It is
noteworthy that the reduced ratio of Teffs to Foxp3+Tregs
and increased frequency of CD62LHI Foxp3+Tregs in the
islets observed 4 weeks post–dsAAV8mIP-IL2 vaccination
(Fig. 2) were also evident in NOD mice monitored for di-
abetes long-term (e.g., up to 23 weeks after dsAAV vacci-
nation) (Fig. 5). This result is particularly striking in view
of the progressive increase in the Teffs to Foxp3+Tregs
ratio, as well as the declining frequency of CD62LHI
Foxp3+Tregs apparent in the islets of 35-week-old control
NOD female mice (Fig. 5D and E), typical of ongoing b-cell
autoimmunity. These findings demonstrate that once es-
tablished, the islet Foxp3+Treg pool is maintained long-
term by persistent b-cell–expressed IL-2. Indeed, similar
numbers of islet Foxp3+Tregs were detected in NOD mice
treated 23 (Supplementary Fig. 4) versus 4 weeks (Fig. 2B)
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FIG. 5. dsAAV8mIP-IL2 prevents diabetes in NOD mice at late preclinical stages. A: Ten- to 12-week-old NOD female mice were treated with 2.5 3
10
10
VPs (n = 9) or 1 3 1010 VPs (n = 8) of dsAAV8mIP-IL2, 2.5 3 1010 VPs of dsAAV8mIP-EGFP (n = 10), or left untreated (n = 22) and monitored
for diabetes. *P < 0.05, ***P < 1023, Kaplan-Meier log-rank test. B: Fifteen- to 16-week-old NOD females were treated with 2.5 3 1010 VPs (n = 5)














T cells were assessed for CD62L expression. *P < 0.05, ***P < 1023, one-way ANOVA 6 SEM. E: The ratio of IFN-g+ Teffs to
Foxp3
+
Tregs was compared between treatment groups in the PLNs and islets. *P < 0.05, **P < 1022, two-way ANOVA 6 SEM.
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post–dsAAVmIP-IL2 vaccination. Whether expression of
b-cell–specific IL-2 is required to maintain islet Foxp3+-
Tregs needs to be determined. Interestingly, dsAAV8mIP-IL2
failed to prevent diabetes in transgenic NOD.8.3 mice ex-
pressing the H2Kd-restricted T-cell receptor specific for
islet-specific glucose-6-phosphatase catalytic subunit-
related protein (Supplementary Fig. 5), suggesting that
Foxp3+Tregs are required for disease prevention; for in-
stance, CD4+ Foxp3+Tregs make up only ,1% of the islet
T cell pool following dsAAV8mIP-IL2 vaccination.
This study further highlights the efficacy of dsAAV
vector–mediated gene transfer to selectively modify the
immunogenicity of b-cells in vivo. Transduction of b-cells
in vivo with a dsAAV vector results in rapid transgene
expression that persists long-term (Fig. 1B); the latter
indirectly demonstrating that b-cell viability and function
are unaffected by dsAAV vector transduction. The use of an
insulin promoter restricts transgene expression to b-cells,
so that high local cytokine levels can be obtained within
the islets and complications associated with systemic cy-
tokine delivery minimized (30). A similar approach has
been taken to target ectopic IL-4 expression to b-cells (35).
Recent technological advances can also be exploited to
refine b-cell specificity and reduce immunogenicity of AAV
capsid proteins, thereby enhancing application of dsAAV
vector gene transfer for the treatment of type 1 diabetes in
the clinic (48).
Our observations are consistent with a model in which
elevated local IL-2 has direct effects on islet Foxp3+Tregs,
only minimal (if any) on islet Teffs, and no effect on non–T
cell islet residents such as NK cells and B cells (Supple-
mentary Fig. 6). An increased pool of islet Foxp3+Tregs
characterized by a phenotypic shift toward CD62LHI
Foxp3+Tregs and increased fitness and suppressor func-
tion effectively blocks ongoing b-cell destruction by Teffs.
Once established, the islet Foxp3+Treg pool is stable and
long-term tolerance maintained. These results provide strong
rationale to further pursue b-cell–specific targeting of IL-2
and other cytokines as a strategy to manipulate islet-resident
Tregs and block the diabetogenic response.
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